{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053598","form_type":"8-K","ticker":null,"cik":"0001845337","company_name":"Day One Biopharmaceuticals, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.735264+00:00","generated_at":"2026-06-02T22:24:20.552830+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Day One Biopharma Q1 net loss $62.4M, launches OJEMDA after April FDA approval","bullets":["Q1 2024 net loss $62.4M vs $42.4M YoY; cash $317.9M expected to fund ops into 2026.","OJEMDA (tovorafenib) received FDA accelerated approval in April for relapsed/refractory BRAF-altered pLGG; first prescriptions written.","R&D expenses $40.2M (up from $27.8M) driven by compensation, PRV buyback, and clinical activities.","Phase 3 FIREFLY-2 front-line pLGG trial enrolling with >90 sites activated globally.","Rare pediatric disease priority review voucher received upon OJEMDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053598","json":"https://secwatch.observer/filing/0000950170-24-053598.json","markdown":"https://secwatch.observer/filing/0000950170-24-053598.md","text":"https://secwatch.observer/filing/0000950170-24-053598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/0000950170-24-053598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/dawn-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:24:20.552830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2aac48c432d9011e20029880b08608d874845c55","claim":"Day One Biopharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income $62.4 million.","evidence_excerpt":"Day One Biopharmaceuticals, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/0000950170-24-053598-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$62.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}